http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : Ciftci Rumeysa (검색결과 2 건)
- 무료
- 기관 내 무료
- 유료
-
Aydiner, Adnan,Ciftci, Rumeysa,Karabulut, Senem,Kilic, Leyla Asian Pacific Journal of Cancer Prevention 2013 Asian Pacific journal of cancer prevention Vol.14 No.10
Aim: To determine whether beta-blockers (BBs) improve the overall survival (OS) of patients with metastatic non-small cell lung cancer (NSCLC). Materials and Methods: The medical charts of 107 patients with metastatic NSCLC were retrospectively assessed. Thirty-five patients (BB group) using BBs during chemotherapy (CT) were compared with 72 controls [control=(C) group] who did not use BBs following the diagnosis of NSCLC. The histological tumor subtype, performance status (ECOG), age, gender, smoking status, comorbidities, other medications and chemotherapeutics that were received in any line of treatment were recorded. We compared the overall survival (OS) of the patients in the BB and C groups. Results: The mean age of the patients was 61 years (range 42-81 years) and all patients were administered CT. The BB group was more likely to have HT and IHD and was more likely to use RAS blockers (p<0.01 for all) compared with the C group, as expected. The mean follow-up time was 17.8 months (range 1-102 months) for the entire group. The most commonly prescribed BB agent was metoprolol (80% of cases). At the time of the analysis, 74 (69%) of all patients had died. In the univariate analysis the median overall survival (OS) was 19.25 (${\pm}2.87$) months (95%CI: 13.62-24.88) in the BB group and 13.20 (${\pm}2.37$) months (95%CI: 8.55-17.85) in the C group (p=0.017). However, the benefit of BBs on survival disappeared in the multivariate analysis. Conclusions: The use of BBs during CT may be associated with an improved OS for patients with metastatic NSCLC.
-
Intolerance to Sunitinib Treatment in Hemodialysis Patients With Metastatic Renal Cell Carcinoma
Ibrahim Yildiz,Fatma Sen,Leyla Kilic,Rumeysa Ciftci,Mert Basaran 대한비뇨의학회 2014 Investigative and Clinical Urology Vol.55 No.1
Sunitinib is a multiple tyrosine kinase receptor inhibitor that is approved for the treatmentof metastatic renal cell carcinoma (RCC). However, neither an appropriate dosenor dosing schedule of sunitinib has yet been established for patients with metastaticRCC who are on hemodialysis. Here, we report on two hemodialysis patients who receivedsunitinib to treat metastatic RCC. Sunitinib was planned to be administeredat a dosage of 25 mg/d for 4 of every 6 weeks. Although sunitinib toxicity was manageablein one patient, disease progression occurred after 4 months of treatment. In the secondpatient, acute pulmonary edema, caused by uncontrolled hypertension, developed onthe 15th day of sunitinib therapy and the drug had to be discontinued. Sunitinib is thusnot well tolerated in a hemodialysis setting. Close monitoring of toxicity and dose manipulationmay be required if such therapy is attempted.
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
